Vicarious Surgical Inc.
Vicarious Surgical Inc. (RBOT) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Vicarious Surgical Inc. (RBOT), covering cash flow, earnings, and balance sheets.
Vicarious Surgical Inc. (RBOT) Income Statement & Financial Overview
View the income breakdown for Vicarious Surgical Inc. RBOT across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $2.09M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $1.04M | $0.00 | $524000.00 | $521000.00 |
| Gross Profit | $1.04M | $0.00 | -$524000.00 | -$521000.00 |
| Gross Profit Ratio | $0.50 | $0.00 | ||
| R&D Expenses | $9.51M | $10.80M | $10.40M | $9.45M |
| SG&A Expenses | $6.51M | $6.96M | $6.79M | $6.14M |
| Operating Expenses | $16.02M | $17.75M | $17.71M | $15.59M |
| Total Costs & Expenses | $17.07M | $17.75M | $17.71M | $16.11M |
| Interest Income | $594000.00 | $802000.00 | $918000.00 | $975000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $542000.00 | $507000.00 | $537000.00 | $521000.00 |
| EBITDA | -$13.38M | -$16.58M | -$14.68M | -$16.48M |
| EBITDA Ratio | -$6.40 | |||
| Operating Income | -$14.98M | -$17.75M | -$17.71M | -$16.11M |
| Operating Income Ratio | -$7.17 | |||
| Other Income/Expenses (Net) | $1.05M | $664000.00 | $2.51M | -$892000.00 |
| Income Before Tax | -$13.93M | -$17.09M | -$15.21M | -$17.001M |
| Income Before Tax Ratio | -$6.66 | |||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $477724.00 |
| Net Income | -$13.93M | -$17.09M | -$15.21M | -$17.001M |
| Net Income Ratio | -$6.66 | |||
| EPS | -$2.36 | -$2.90 | -$2.59 | -$2.91 |
| Diluted EPS | -$2.36 | -$2.90 | -$2.59 | -$2.91 |
| Weighted Avg Shares Outstanding | $5.91M | $5.90M | $5.87M | $5.85M |
| Weighted Avg Shares Outstanding (Diluted) | $5.91M | $5.90M | $5.87M | $5.85M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q1 2024 to $2.09M in Q4 2024. Gross profit remained healthy with margins at 50% in Q4 2024 compared to N/A in Q1 2024. Operating income hit -$14.98M last quarter, sustaining a consistent -717% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$13.38M. Net income rose to -$13.93M, while earnings per share reached -$2.36. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan